Pain Therapeutics (NASDAQ:PTIE) shares saw unusually-strong trading volume on Thursday . Approximately 204,577 shares were traded during trading, an increase of 69% from the previous session’s volume of 120,722 shares.The stock last traded at $2.50 and had previously closed at $2.37.

Separately, Zacks Investment Research lowered shares of Pain Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th.

The stock’s market capitalization is $121.81 million. The stock’s 50-day moving average price is $2.19 and its 200-day moving average price is $2.09.

Pain Therapeutics (NASDAQ:PTIE) last issued its quarterly earnings data on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.07. On average, equities research analysts predict that Pain Therapeutics will post ($0.54) earnings per share for the current fiscal year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.